Holding(s) in Company

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

VERONA PHARMA PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

·

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify) :

3. Full name of person(s) subject to the notification obligation: iii

ARIX BIOSCIENCE HOLDINGS LTD &

WALES LIFE SCIENCES INVESTMENT FUND LP 'AFFILIATED' ENTITIES

4. Full name of shareholder(s)

(if different from 3.):iv

5. Date of the transaction and date on

which the threshold is crossed or reached: v

28 JULY 2016

6. Date on which issuer notified:

29 JULY 2016

7. Threshold(s) that is/are crossed or reached: vi, vii

10.6%

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of

shares

if possible using the ISIN CODE

Situation previous to the triggering

transaction

Resulting situation after the triggering transaction

Number

of

Shares

Number

of

Voting

Rights

Number

of shares

Number of voting

rights

% of  voting rights x

Direct

Direct xi

Indirect  xr r

Direct

Indirect

ORDINARY

207 ,500,000

207,500,000

272,017,620

272,017,620

10.6%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial

instrument

Expiration date XI II

Exercise/

Conversion Period xrv

Number of voting

rights that may be acquired if the instrument is exercised! converted.

%of voting

rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

XV, XV i

Resulting situation after the triggering transaction

Type of financial

instrument

Exercise

price

Expiration date XV II

Exercise/

Conversion period xviii

Number of voting rights

instrument refers to

%of voting rights xix,

XX

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

272,017,620

10.6%

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting  rights:

13. Additional information:

14. Contact name:

15. Contact telephone  number:

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

Arix Bioscience Holdings Ltd

Wales Life Sciences Investment Fund LP

Contact address

(registered office for legal entities)

20 Berkeley Square London W1J 6EQ

Phone number & email

020-7290-1050

Other useful information

(at least legal representative for legal persons)

8: Identity of the notifier, if applicable

Full name

James Rawlingson

Contact address

20 Berkeley Square London W1J 6EQ

Phone number & email

020-7290-1050

lnfo@arixbioscience .com

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)